Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.

@article{Allers2011EvidenceFT,
  title={Evidence for the cure of HIV infection by CCR5$\Delta$32/$\Delta$32 stem cell transplantation.},
  author={Kristina Allers and Gero H{\"u}tter and J{\"o}rg Hofmann and Christoph Loddenkemper and Kathrin Rieger and Eckhard Thiel and Thomas Schneider},
  journal={Blood},
  year={2011},
  volume={117 10},
  pages={
          2791-9
        }
}
HIV entry into CD4(+) cells requires interaction with a cellular receptor, generally either CCR5 or CXCR4. We have previously reported the case of an HIV-infected patient in whom viral replication remained absent despite discontinuation of antiretroviral therapy after transplantation with CCR5Δ32/Δ32 stem cells. However, it was expected that the long-lived viral reservoir would lead to HIV rebound and disease progression during the process of immune reconstitution. In the present study, we… 

Tables from this paper

Blocking Formation of the Stable HIV Reservoir: A New Perspective for HIV-1 Cure
TLDR
It is proposed that combining ART initiation with inhibition of IL-7/IL-7R signaling to block CD4- T cell memory formation will limit the generation of long-lived HIV-infected CD4+ T cells and reduce the overall size of the stable HIV-1 reservoir.
HIV-specific CD8⁺ T cells and HIV eradication.
TLDR
The antiviral properties of HIV-specific CD8+ T cells are addressed and how these cells might be harnessed to greater effect toward achieving viral eradication or a functional cure are addressed.
Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model.
TLDR
Data suggest that hematopoietic stem cells protection may be a potential alternative to conventional antiretroviral therapy in patients with HIV/AIDS.
Genetic Modulation Therapy Through Stem Cell Transplantation for Human Immunodeficiency Virus 1 Infection
TLDR
Two facets of HSC genetic treatment for potentially life-threatening HIV infection are concentrated on: building HIV-resistant cells and designing cells that can target HIV disease.
HIV-1 Latency and Eradication: Past, Present and Future.
TLDR
Current efforts to eradicate HIV-1 from this cell population focus primarily on a "shock and kill" approach through cellular reactivation to trigger elimination of virus producing cells by cytolysis or host immune responses, but studies revealed several limitations to this approach that require more investigation to assess its clinical application.
HIV Replication Is Not Controlled by CD8+ T Cells during the Acute Phase of the Infection in Humanized Mice
TLDR
The results strongly suggest that viral replication during the acute phase of the infection in humanized mice is mainly constrained by the number of available targets in lymphoid tissues rather than by CD8+ T cells.
Novel cell and gene therapies for HIV.
TLDR
A series of ongoing and planned trials to establish proof of concept for strategies that could lead to successful cell and gene therapies for HIV are under way, and the eventual goal of these studies is to eliminate latent viral reservoirs and the need for lifelong antiretroviral therapy.
The effect of timing of antiretroviral therapy on CD4+ T-cell reconstitution in the intestine of HIV-infected patients.
TLDR
Mucosal CD4(+) T-cell numbers can be preserved if cART is initiated in acute HIV infection and in chronically HIV-infected patients, early cART improves mucosal CD5-cell differentiation but cannot prevent the persistent lack of total CD4-+) T cells.
From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation
TLDR
Studies of allogeneic SCT in people with HIV have provided important insights into the size and nature of the HIV reservoir, and have invigorated other gene therapies to achieve HIV cure.
Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant
TLDR
Reductions in HIV latency and viral-specific humoral responses with respect to factors associated with allo-HSCT in the absence of HIV resistance factors, such as CCR532 mutation are analyzed.
...
...

References

SHOWING 1-10 OF 54 REFERENCES
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.
TLDR
It is suggested that the GALT may play a major role in the persistence of HIV in such individuals who had been receiving effective antiviral therapy for prolonged periods of time, and a possible mechanism for the maintenance of viral reservoirs revolving around the Galt of HIV-infected individuals despite long-term viral suppression is provided.
Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract
TLDR
It is demonstrated that although chronic suppression of HIV-1 permits near-complete immune recovery of the peripheral blood CD4+ T cell population, a significantly greater CD4- T cell loss remains in the GI mucosa, despite up to 5 yr of fully suppressive therapy.
Transplantation of selected or transgenic blood stem cells – a future treatment for HIV/AIDS?
TLDR
Improvement of HIV-1 therapy that interferes with the entry mechanism seems to be a promising approach in HIV- 1-infected patients with no matching CCR5-delta32 deleted donor.
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
TLDR
Stem cells from a donor who was homozygous for CCR5 delta32 were transplanted in a patient with acute myeloid leukemia and HIV-1 infection and the patient remained without viral rebound 20 months after transplantation and discontinuation of antiretroviral therapy.
CCR5Δ32 Protein Expression and Stability Are Critical for Resistance to Human Immunodeficiency Virus Type 1 In Vivo
TLDR
The hypothesis that the CCR5Δ32 protein actively confers resistance to HIV-1 in vivo is supported and the results suggest that other cellular or virally induced factors may be involved in the stability of CCR 5Δ 32 protein.
Viral Suppression and Immune Restoration in the Gastrointestinal Mucosa of Human Immunodeficiency Virus Type 1-Infected Patients Initiating Therapy during Primary or Chronic Infection
TLDR
The findings suggest that the discordance in CD4+ T-cell restoration between GALT and peripheral blood during therapy can be attributed to the incomplete viral suppression and increased immune activation and inflammation that may prevent restoration of CD4- T cells and the gut microenvironment.
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection
TLDR
The data demonstrate that over one-half of all memory CD4+ T cells in SIV-infected macaques are destroyed directly by viral infection during the acute phase—an insult that certainly heralds subsequent immunodeficiency.
A Preponderance of CCR5+CXCR4+ Mononuclear Cells Enhances Gastrointestinal Mucosal Susceptibility to Human Immunodeficiency Virus Type 1 Infection
TLDR
The gastrointestinal mucosa represents a favored target for HIV-1, in part due to its large population of CXCR4+ CCR5+target cells and not to differences in the virus that it contains.
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.
TLDR
Partial sequencing of HIV pol revealed no new drug resistance mutations or discernible evolution, providing evidence for viral latency rather than drug failure.
Role for CCR5Δ32 Protein in Resistance to R5, R5X4, and X4 Human Immunodeficiency Virus Type 1 in Primary CD4+ Cells
TLDR
It is demonstrated that efficient expression of the CCR5Δ32 protein in primary CD4+ cells by use of a recombinant adenovirus was able to down-regulate surface expression of both wild-type C CR5 and CXCR4 and to confer broad resistance to R5, R5X4, and X4 HIV type 1 (HIV-1).
...
...